Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363:943-53; PMID:20818904; http://dx.doi.org/10.1056/NEJMoa0908806
   PubMed Web of Science ®Google Scholar
• Chene G, Dauplat J, Radosevic-Robin N, Cayre A, Penault-Llorca F. Tu-be or not tu-be: that is the question…about serous ovarian cancer carcinogenesis. Crit Rev Oncol Hematol 2013; 88:134-43; PMID:23523591; http://dx.doi.org/10.1016/j.critrevonc.2013.03.004
   PubMed Web of Science ®Google Scholar
• Sorensen RD, Schnack TH, Karlsen MA, Hogdall CK. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities – a systematic review. Gynecol Oncol 2015; 136:571-81; PMID:25615934; http://dx.doi.org/10.1016/j.ygyno.20-15.01.534
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Baert T, Timmerman D, Vergote I, Coosemans A. Immunological parameters as a new lead in the diagnosis of ovarian cancer. Facts Views Vis Obgyn 2015; 1:67-72; PMID:25897373
   Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348-53; PMID:20693846; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13:739-52; PMID:24060865; http://dx.doi.org/10.1038/nrc3581
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-Associated Macrophages: From Mechanisms to Therapy. Immunity 2014; 41:49-61; PMID:25035953; http://dx.doi.org/10.1016/j.immuni.2014.06.010
   PubMed Web of Science ®Google Scholar
• Rabinovich GA, Ilarregui JM. Conveying glycan information into T cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 2009; 230:144-59; PMID:19594634; http://dx.doi.org/10.1111/j.1600065X.2009.00787.x
   PubMed Web of Science ®Google Scholar
• Ito K, Stannard K, Gabutero E, Clark AM, Neo S-Y, Onturk S, Blanchard H, Ralph SJ. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31:763-78; PMID:22706847; http://dx.doi.org/10.1007/s10555-012-9388-2
   PubMed Web of Science ®Google Scholar
• Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, Garcia-Vallejo JJ, Ouyang J et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014; 156:744-58; PMID:24529377; http://dx.doi.org/10.1016/j.cell.2014.01.043
   PubMed Web of Science ®Google Scholar
• Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H, Li Z. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5:e991; PMID:24407244; http://dx.doi.org/10.1038/cddis.2013.526
   PubMedGoogle Scholar
• Verschuere T, Van Woensel M, Fieuws S, Lefranc F, Mathieu V, Kiss R, Van Gool SW, De Vleeschouwer S. Altered galectin-1 serum levels in patients diagnosed with high-grade glioma. J Neurooncol 2013; 115:9-17; PMID:23824536; http://dx.doi.org/10.1007/s11060-013-1201-8
   PubMed Web of Science ®Google Scholar
• Napoletano C, Bellati F, Landi R, Pauselli S, Marchetti C, Visconti V, Sale P, Liberati M, Rughetti A, Frati L et al. Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppression. J Cell Mol Med 2010; 14:2748-59; PMID:19780872; http://dx.doi.org/10.1111/j.1582-4934.2009.00911.x
   PubMed Web of Science ®Google Scholar
• Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett 2010; 31:375-83; PMID:20588232.
   PubMed Web of Science ®Google Scholar
• Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A et al. Immunosuppression through constitutively activated NF-κB signalling in human ovarian cancer and its reversal by an NF-κB inhibitor. Br J Cancer 2014; 110:2965-74; PMID:24867687; http://dx.doi.org/10.1038/bjc.2014.251
   PubMed Web of Science ®Google Scholar
• Svendsen MN, Werther K, Nielsen HJ, Kristjansen PEG. VEGF and tumour angiogenesis. Impact of surgery, wound healing, inflammation and blood transfusion. Scand J Gastroenterol 2002; 37:373-9; PMID:11989825; http://dx.doi.org/10.1080/003655202317315971
   PubMed Web of Science ®Google Scholar
• Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, Pecorelli S, Santin AD, Ravaggi A. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol 2012; 2012:245756; PMID:22792477; http://dx.doi.org/10.5402/2012/245756
   PubMedGoogle Scholar
• Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Lueller V. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer 2010; 10:139; PMID:20388222; http://dx.doi.org/10.1186/1471-2407-10-139
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Pickart a-K, Fuhljahn C, Friepoertner T, Schlehe B, Biesterfeld S, Schroeder W. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006; 16 Suppl 1:183-9; PMID:16515588; http://dx.doi.org/10.1111/j.1525-1438.2006.00307.x
   PubMed Web of Science ®Google Scholar
• Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol 2013; 128:391-6; PMID:23142075; http://dx.doi.org/10.1016/j.ygyno.2012.11.002
   PubMed Web of Science ®Google Scholar
• Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008; 229:172-83; PMID:18313712; http://dx.doi.org/10.1016/j.taap.2008.01.009
   PubMed Web of Science ®Google Scholar
• Strik HM, Schmidt K, Lingor P, Tönges L, Kugler W, Nitsche M, Rabinovich GA, Bähr M. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 2007; 18:483-8; PMID:17611674; http://dx.doi.org/10.3892/or.18.2.483
   PubMed Web of Science ®Google Scholar
• Kim H-J, Jeon H-K, Cho YJ, Park YA, Choi J-J, Do I-G, Song SY, Lee YY, Choi CH, Kim TJ et al. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 2012; 48:1914-21; PMID:22386573; http://dx.doi.org/10.1016/j.ejca.2012.02.005
   PubMed Web of Science ®Google Scholar
• Chung LY, Tang SJ, Sun GH, Chou TY, Yeh TS, Yu SL, Sun KH. Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 2012; 18:4037-47; PMID:22696230; http://dx.doi.org/10.1158/1078-0432.CCR-11-3348
   PubMed Web of Science ®Google Scholar
• Falcão-Júnior JO, Teixeira-Carvalho A, Cândido EB, Lages EL, Ferreira Freitas GG, Lamaita RM, Freire Bonfim LP, Borges Salera R, Traiman P P, da Silva-Filho AL. Assessment of chemokine serum levels in epithelial ovarian cancer patients. Tumori 2013; 99:540-4; PMID:24326845; http://dx.doi.org/10.1700/1361.15108
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:981-7; PMID:15824174; http://dx.doi.org/10.1158/1055-9965.EPI-04-0404
   PubMed Web of Science ®Google Scholar
• Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainze C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999; 81:855-9; PMID:10555758; http://dx.doi.org/10.1038/sj.bjc.6690776
   PubMed Web of Science ®Google Scholar
• Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol 2009; 114:12-7; PMID:19398128; http://dx.doi.org/10.1016/j.ygyno.2009.03.028
   PubMed Web of Science ®Google Scholar
• Li M, Knight DA, A Snyder L, Smyth MJ, Stewart TJ. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology 2013; 2:e25474; PMID:24073384; http://dx.doi.org/10.4161/onci.25474
   PubMed Web of Science ®Google Scholar
• Wang HW, Joyce JA. Alternative activation of tumor-associated macrophages by IL-4: Priming for protumoral functions. Cell Cycle 2010; 9:4824-35; PMID:21150330; http://dx.doi.org/10.4161/cc.9.24.14322
   PubMed Web of Science ®Google Scholar
• Landskron G, De La Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014; 2014:149185; PMID:24901008; http://dx.doi.org/10.1155/2014/149185.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer 2012; 131:344-56; PMID:21858811; http://dx.doi.org/10.1002/ijc.26366
   PubMed Web of Science ®Google Scholar
• Zhang X, Weng W, Xu W, Wang Y, Yu W, Tang X, Ma L, Pan Q, Wang J, Sun F. Prognostic significance of interleukin 17 in cancer: a meta-analysis. Int J Clin Exp Med 2014; 7:3258-69; PMID:25419357
   PubMed Web of Science ®Google Scholar
• Yao F, Yan S, Wang X, Shi D, Bai J, Li F, Sun B, Qian B. Role of IL-17F T7488C polymorphism in carcinogenesis: a meta-analysis. Tumor Biol 2014; 35:9061-8; PMID:24913709; http://dx.doi.org/10.1007/s13277-014-2171-y
   PubMed Web of Science ®Google Scholar
• Lan C, Huang X, Lin S, Huang H, Cai Q, Lu J, Liu J. High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res 2013; 352:351-9; PMID:23397428; http://dx.doi.org/10.1007/s00441-013-1567-0
   PubMed Web of Science ®Google Scholar
• Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine 2015; 73:108-13; PMID:25743245; http://dx.doi.org/10.1016/j.cyto.2015.01.035
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 2007; 109:1568-73; PMID:17023580; http://dx.doi.org/10.1182/blood-2006-06-031856
   PubMed Web of Science ®Google Scholar
• Chang CI, Liao JC, Kuo L. Macrophage arginase promotos tumor cell growth and suppresses nitric-mediated tumur cytotoxicity. Cancer Res 2001; 61:1100-6; PMID:11221839
   PubMed Web of Science ®Google Scholar
• Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Philips GM et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014; 513:559-63; PMID:25043024; http://dx.doi.org/10.1038/nature13490
   PubMed Web of Science ®Google Scholar
• Casazza A, Laoui D, Wenes M, Rizzolio S, Bassani N, Mambretti M, Deschoemaeker S, Van Ginderachter JA, Tamagnone L, Mazzone M. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013; 24:695-709; PMID:24332039; http://dx.doi.org/10.1016/j.ccr.2013.11.007
   PubMed Web of Science ®Google Scholar
• Yigit R, Massuger LFAG, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010; 117:366-72; PMID:20144842; http://dx.doi.org/10.1016/j.ygyno.2010.01.019
   PubMed Web of Science ®Google Scholar
• Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7:651-8; PMID:21647333; http://dx.doi.org/10.7150/ijbs.7.651
   PubMed Web of Science ®Google Scholar
• Komiyama S, Kurahashi T, Ishikawa M, Tanaka K, Komiyama M, Mikami M, Udagawa Y. Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin. Oncol Rep 2011; 25:1131-8; PMID:21249319; http://dx.doi.org/10.3892/or.2011.1151
   PubMed Web of Science ®Google Scholar
• Tas F, Karabulut S, Serilmez M, Ciftci R, Duranyildiz D. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer. Tumor Biol 2013; 1:1-8; PMID:24307621; http://dx.doi.org/10.1007/s13277-013-1401-z
   Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29:313-26; PMID:19441883; http://dx.doi.org/10.1089/jir.2008.0027
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. Targeting chemokine (C-C motif) Ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci 2010; 95:31-53; PMID:21075328; http://dx.doi.org/10.1016/B978-0-12-385071-3.00003-4
   PubMed Web of Science ®Google Scholar
• Getter MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S. Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer 2010; 20:918-25; PMID:20683396; http://dx.doi.org/10.1111/IGC.0b013e3181e5c442
   PubMed Web of Science ®Google Scholar
• Fader AN, Rasool N, Vaziri SAJ, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L et al. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res 2010; 30:4791-8; PMID:21187454
   PubMed Web of Science ®Google Scholar
• Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: Analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein I in the paclitaxel-resistant phenotype. Clin Cancer Res 1999; 5:3445-53; PMID:10589757
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013; 13:871-82; PMID:24263190; http://dx.doi.org/10.1038/nrc3627
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014; 26:605-22; PMID:25517747; http://dx.doi.org/10.1016/j.ccell.2014.10.006
   PubMed Web of Science ®Google Scholar
• Kandukuri SR, Rao J. FIGO 2013 staging system for ovarian cancer: what is new in comparison to 1988 staging system? Curr Opin Obstet Gynecol 2015; 27:48-52; PMID:25490382; http://dx.doi.org/10.1097/GCO.0000000000000135
   PubMed Web of Science ®Google Scholar